Virotherapy Insider – Oncolytic Virus Deep Dive Part 1
Despite advances in recent decades, traditional cancer therapies, from surgery, to chemo-, radiation and hormone therapy, have their drawbacks hindering improvement in cancer mortality rates. They are invasive, bring toxic side effects and, in many cases, only offer a limited extension to patient life expectancy.
Oncolytic viruses (OVs) are a promising new approach to this field, showing exciting potential to revolutionize cancer treatment and deliver on the “moonshot” promise of curing the disease.
However, they remain in their infancy. What is holding them back from truly achieving their full potential, and how can obstacles be overcome?
In our latest edition of Virotherapy Insider: Deep Dive we will explore the unique benefits of OVs, and how companies can overcome commercialization challenges to deliver OVs to market.
In part 1, you will learn:
- The advantages of OVs in treating cancer
- The challenges faced by OVs during development and commercialization
- How virotherapy specialist CDMOs can help overcome obstacles and support market adoption